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ABSTRACT
Overwhelming evidence now points to asthma as a chronic 
inflammatory disease involving the airways. The T lymphocyte 
takes primacy in driving the inflammatory response through 
upregulation of cytokines, specifically those encoded in the 
IL-4 gene cluster: IL-4 and IL-13 (IgE isotype switching); IL-3, 
IL-5 and GM-CSF (eosinophil and basophil recruitment); and 
IL-9 (mast cell maturation). Additional cytokines of importance 
include TNFƒ¿ and a range of related C-x-C and C-C cytokines. 
Although allergens are involved in initiating the Th-2 T-cell 
response, other factors are likely to operate that expand 
and maintain the inflammatory reaction. These include a poten-
tial role for superantigens and autoimmune mechanisms as 
well as the recruitment of accessory cytokine producing cells, 
especially mast cells and eosinophils. Leucocytes recruited 
from the microvasculature through interactions with specific 
adhesion molecules release an array of mediators, which in 
addition to causing bronchoconstriction also lead to damage 
to the epithelium and underlying structures. Neutral pro-
teases from mast cells, metalloproteases from eosinophils 
and an array of mediators from the formed elements of the 
airway all contribute to the tissue destruction remodelling 
process. It was concluded that asthma is a dynamic disease 
process involving an interplay between inflammation and 
repair processes and that the differing proportions of these 
could account for the various disease phenotypes associated 
with severity and progression.
Key words: asthma, cytokines, eosinophils, inflammation, 
mast cells, repair, T cells.
THE HEALTH AND ECONOMIC BURDEN OF ASTHMA 
Statistics worldwide indicate that the prevalence of asthma con-
tinues to increase, and the UK is no exception. However, the 
major health burden of asthma relates to severe, chronic and
relapsing disease. The recent WHO/NHLBI technical report on 
A Global Strategy for Asthma describes severe persistent asthma 
as frequent or continuous daily symptoms despite treatment, fre-
quent sleep disturbance on account of asthma, severe physical 
and other lifestyle limitations, peak expiratory flow (PEF) or 
forced expiratory volume in IS (FEV1) <60% predicted, and 
within and between day variability of PEF>30%.1 Much of the 
mortality and some of the morbidity of asthma results from 
underestimation of the severity of the disease by both patient 
and doctor, inadequate action at the onset of deterioration and 
undertreatment. However, there remain many patients who 
receive anti-asthma drugs in large doses and yet remain symp-
tomatic. The clinical phenotype of such patients is often com-
plex and varied with no single pattern dominating. 
  The cost of illness for adult asthma, analysed by disease 
severity, reveals a disproportionate use of medical resources by 
patients with severe disease. In Canada, severe asthma com-
prised 10% of the asthma population and accounted for 51% of 
all direct medical care costs and 54% of total asthma costs.2 
Patients with severe disease were three times more likely to con-
sult an asthma specialist, 15 times more likely to use an acci-
dent and emergency department and 19 times more likely to 
require hospitalization. In Australia, severe asthma comprises 
6% of the adult asthma population and consumes 47% of the 
total annual costs for this disease; an estimate similar to that for 
the UK. Thus, on the grounds of unsatisfactory treatment, qual-
ity of life and health economics, there is a strong case for focus-
ing attention on this group of asthma patients.
CYTOKINE AND MEDIATOR NETWORKS AS THE BASIS 
OF ASTHMA
Asthma is a multifactorial disease that spans the full spectrum of 
activity from mild seasonal symptoms to being severe and 
intractable. When classifying asthma by severity, the majority falls 
into the mild-moderate range and can be managed well with 
currently available drugs. It is also at this end of the disease 
spectrum and in those with atopy that most of our understanding 
of inflammatory and mediator mechanisms of asthma has 
been based. Application of immunohistochemistry, in situ hybridiza-
tion (ISH) and reverse transcriptase polymerase chain reaction 
(RT-PCR) to lavage cells, mucosal biopsies and T cells from the
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Fig. 1 Cell co-operation in allergy. Schematic representation of the 
key cytokine involved in the regulation of allergic inflammation.
airways of such patients reveals upregulation of the IL-4 gene 
cluster (IL-4, IL-13, IL-5, IL-3, IL-6, GM-CSF, IL-9) in T cells, mast 
cells and eosinophils. These cytokines are of crucial importance 
in the initiation and maintenance of the allergic inflammatory 
response through isotype switching of B cells to IgE synthesis 
(IL-4, IL-13), the selective maturation of Th2-like CD4+ T cells 
expressing the IL-4 gene cluster (IL-4), growth, maturation and 
activation of eosinophils and basophils (IL-3, IL-5, GM-CSF) and 
maturation of mast cells (SCF, IL-6, IL-9; Fig. 1). The expression
of a counter regulatory signal provided by IFN-γ(from Th-1 cells)
and macrophage/monocyte derived IL-12, which induces its syn-
thesis, becomes reduced. This has led to the concept that 
cytokines from the Th-2 subtype of T cell dominate over those of 
the Th-1 subtype, leading to expression of the eosinophilic bron-
chitis characteristic of asthma. While far less is known of the 
cytokine networks in asthma, other than that associated with 
atopy, the therapeutic efficacy of disease-modifying drugs, espe-
cially corticosteroids, is likely to be the consequence of transcrip-
tion factor-mediated downregulation of cytokine production and 
the pro-inflammatory pathways that these signalling molecules 
influence.
MECHANISMS OF ASTHMA SEVERITY AND 
CHRONICITY
There is overwhelming evidence to indicate that airway inflam-
mation underlies the pathophysiology of asthma, but its rela-
tionship to disease severity is less clear. While there are 
eosinophils in the sputum, a persistent blood eosinophilia with 
increased circulating levels of eosinophil granule proteins 
broadly relates to disease severity. These measures are too vari-
able to provide clinically useful markers to predict the level of 
airway inflammation.
 The selective recruitment of cells from the microvasculature 
underlies the ongoing inflammation in severe and chronic dis-
ease. Increased mast cell, eosinophil and T cell survival through 
cytokine-mediated inihibition of apoptosis is also important. 
Lung transplantation has shown that alone, with its lymphoid tis-
sue, the lung is able to sustain ongoing asthma also emphasiz-
ing the importance of local factors.3 From a thera-
peutic standpoint the wide variation observed in these biomark-
ers in relation to the varied clinical phenotypes suggest complex 
cellular and mediator mechanisms. 
 Corticosteroids are highly effective anti-asthma drugs acting 
to reduce the inflammatory response. However, there are many 
patients in whom only partial relief is achieved even with high 
doses. In a well-defined population of'corticosteroid-resistant'
asthmatics with preservation of β2-agonist bronchodilatation,
abnormalities of circulating monocyte and T-cell cytokine func-
tion have been described.4 However, such patients represent 
only a minority of the'difficult to control' asthmatics. 
 The majority of asthma occurs in association with atopy, the 
predisposition to generate IgE in response to common environ-
mental allergens through a Th-2-cell-dependent mechanism. 
Ongoing allergen-specific IgE production in severe disease 
provides the rationale for allergen avoidance and high altitude 
treatment. However, environmental interventions have no effect 
on non-allergic asthma and many patients with severe atopic 
disease only partially respond or fail to respond. Irrespective of 
atopy, powerful epidemiological studies have linked the total 
serum IgE to the presence of asthma and its level of disease pro-
gression.5 There have been very few long-term studies but what 
evidence does exist suggests that severe and poorly controlled 
asthma progresses because of an increasing, irreversible com-
ponent.6 Severe and prolonged inflammation is almost always 
accompanied by tissue remodelling. The airways are no excep-
tion; however, the mechanism(s) involved and their contribution 
to the overall pathophysiology of severe and chronic asthma 
have not been evaluated.
It follows that the severity and chronicity of asthma results 
from the dysregulation of cytokine networks leading to persistent 
inflammation in structurally altered airways which become 
refractory to treatment. The responsibility for disease progres-
sion does not lie with any single cellular element but embraces T 
and B cells, mast cells, eosinophils, endothelial cells, epithelial 
cells and myofibroblasts acting co-operatively with each other 
and with formed elements of the airways, including smooth 
muscle and nerves, leading to the variable phenotype charac-
teristic of severe disease. This integrated view of asthma as a 
chronic disease of ongoing inflammation and repair leads us to 
incriminate a number of effector cells.
Continuous T-cell activation 
Severe disease increasingly engages airway T cells leading to 
their oligoclonal expansion, activation with a mixed pattern of
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cytokine expression and failure of normal counter regulatory
mechanisms.
  T-cell activation and expression of mRNA for cytokines is a
common feature of all types of asthma. In mild disease, the level
of T-cell involvement in the airways is low, but there is ample
evidence for mast cell and eosinophil activation, which may
explain why cromone-like drugs are more efficacious at this end
of the asthma spectrum. By contrast our biopsy and lavage study
of patients admitted to the Dutch Asthma Centre in Davos,7
together with observations of severely symptomatic asthmatic
patients in the UK taking high doses of inhaled corticosteroids
indicate that activated T celis drive the ongoing inflammatory
process in severe disease by mechanisms in addition to
eosinophil recruitment and activation. At 24 h after allergen
challenge, we and others have shown increased IL-5 transcrip-
tion in relation to T-cell recruitment and activation supporting
the Th-2 hypothesis;8 however, our T-cell cloning studies have
shown that lavage T cells from asthmatics of differing disease
severity exhibit considerable heterogeneity of cytokine expres-
sion.9-10 At baseline, T cells from atopic asthmatic airways show
strong expression of mRNA for IL-13, GM-CSF, IFN-γ and TNF-
α whereas with allergen instillation there was a cytokine shift in
favour of IL-3, IL-4, IL-5 and IL-13and away from IFN-γ and
TNF-α.. These data support the recent T-cell cloning studies that
recognize the existence of Th-2-like cells that are allergen
responsive, while the majority of activated airway T cells in the
airways serve other functions.11
  Using monensin to inhibit Golgi-mediated cytokine transport
and flow cytometry applied to permeabilized cells, we have
evaluated the cytokine protein production by airway T cells.
Confirming our observations on airway T-cell clones, a high
proportion of asthmatic BAL T cells produced IFN-γ and/or IL-2
and only a few accumulated IL-4 or IL-5.10 Even more surprising
was the finding that in asthma cases, compared to normal con-
frois,there is a significantly greater production of IFN-γ but not
IL-2. During acute exacerbations of asthma there is evidence for
T-cell upregulation in the peripheral circulation accompanied
by enhanced IL-5 gene expression. However, during acute
episodes in cases in the UK we have shown that proliferative T-
cell responses to the house dust mite allergen, when compared
with responses before or 8 weeks after the episode, decreased
rather than increased indicating that factors influencing T cells
other than allergens are important in directing the immune
response during exacerbations.It is clear that little is known
about T-cell cytokine responses influencing disease chronicity
and severity in patients with asthma and howthey may escape
corticosteroid suppression.
  Based on lung transplant experiments and bronchoscopy
studies in mild-moderate disease, an important aspect of T-cell
involvement is local expression. Studying the T-cell receptor
(TCR)c V-gene usage will shed light on factors that shape the
airway's T-cell repertoire. In normal subjects, the peripheral TcR
repertoire is diverse, resulting from the use of different VD and J
s gments in forming the α and β chain. As a consequence non-
specific recruitment would result in a heterogeneous TcR reper-
toire at the inflammatory site, reflecting the popuiations in
blood. The exciting observation that atopy (and asthma) is asso-
ciated with inkage to specific polymorphisms of the Vα reper-
toire on chromosome 14 indicates that genetic determinants
involving allergen recognition are an important component of
T-cell selection.12 Specific stimulation of T cells would modify
he Vα and Vβ repertoi e so th t allergen-driven responses
would result in dominant oligoclonal T-cell interaction whereas
superantigens would select a single dominant TcR Vα and Vβ
family, bu  with random use of DJ segments. In preliminary
experiments we have amplified the TcR repertoire in airways
by polymerase chain re ction(PCR)of cDNA prepared from
broncho-alveolar lavage (BAL) and blood lymphocytes of the
same subjects and have found that TcR Vβ seledion in favour of
VH5 is a feature of airway T cells in atopic asthma.This supports
the role of superantigens in driving the immune response.13
Thes  promising initial experiments need to be expanded to
embrace more exaggerated forms of the disease in the presence
and absence of atopy.
Mast cells and eosinophils
The mast cell and eosinophil contribute to the maintenance of
mucosal inflammation through their elease of pro-inflamma-
tort cytokines and mediators.
Mast cell subtypes
he mastcell has long been regarded as an important effector
cell of sthma through its capacity to respond to IgE-dependent
activation with release of both preformed and newly generated
m ia ors.This function has found wide acceptance as the cause
of acute allergen-induced and exercise-induced bronchocon-
strict on. We believe that as a constituent cell of the airway, the
mast cel  also p ys a key role n maintaining chronicity of the
inflammatory response. Of the two types of mast cell phenotyped
through t eir granule neutral protease content, it is that contain-
ing only the unique four- hained neutral protease, tryptase, that
dominates(MCT), although tryptase-containing and chymase-
containingcells (MCTC) are found in relation to the submucous
glands and microvasculature. Both MCT and MCTC require stem
cell factor (SCF, c-kit ligand) for survival; MCT cells are under the
influence of T-cell cytokines (IL-6, IL-9) while the MCTC phenotype
is determined by fibroblast-derived growth factors. The relevance
of mast cell products to asthma has been revealed in a study of
151 patientswith different types of asthma in BAL fluid. The prod-
ucts of mastcell activation, tryptase, histamine and PGD2 were
all present in higher oncentrations than in normal patients with
levels hat correlated po itively with albumin as a marker of
mic ovasc lar permeability (P<0.01) and negatively with FEV1,
su gesting an important link to disease activity.
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Mast cell cytokines
The importance of IL-4 and IL-5 in the pathogenesis of asthma
is well established but, until recently, it was thought that their
major source was the Th-2-like helper T cell. As an alternative
source, we have shown that human mast cells are an important
source of IL-4, IL-5, IL-6, IL-8 and TNFα..14,15 Both by immuno-
histochemistry and immunoelectronmicroscopy we a e the first
to show that human mast cells contain granule-associated IL-4,
IL-5, IL-6 and TNF-α and that these are differentially expressed
between the two mast cell subtypes.16 In purified lung mast cells
mRNA for all of these cytokines is induced by IgE-dependent
activation and is followed by protein secretion for up to 48h.17
The inducing stimuli for secretion appears to be different, IL-4
and IL-5 being more dependent upon FcεR1 receptor signalling,
while SCF initiates TNF-α production. Both IL-6 and IL-8 mRNA
is constitutively expressed at a high level, although IL-6 transcrip-
tion could be further enhanced with SCF. Our recent
finding that in severe atopic disease a proportion of MCT cells
also contain preformed SCF provides an autocrine mechanism
for local mast cell survival and activation. Since every mast cell
is antigen specific, whereas this antigen specificity applies to
only 1 in 300-5000 airway T cells, we hypothesize that cytokine
release from airway mast cells initiated by allergens or other
stimuli is pivotal in the induction and maintenance ofthe inflam-
matory response through upregulation of IgE (IL-4, IL-6), Th-2-
like T cells (IL-4), mast cell (IL-6, SCF), eosinophil(IL-5, IL-8) and
vascular adhesion mol cule (TNF-α, IL-4) functions.
  The use of monoclonal antibodies (mAb) directed to different
pitopes of IL-4 in glycomethacrylate sections of biopsies and
free mas  cells has allowed us to differentiate preformed
(mAb4D9) from the secreted (mAb 3H4) form of the cytokine.15
In both opic and non-atopic asthma the proportion of
bronchial mast cells demonstrating ring staining with 3H4 is
consid rably greater than in normal subjects, indicating ongoing
cytokine release in the absence of specific challenge. Seasonal
xp sure to allergens increases,18 whereas treatment with
inhaled corticosteroids decreases19 the number of 3H4+ mast
cells without altering the overall number of cells staining with
4D9 for the preformed cytokine, indicating that IL-4 secretion is
sensitive to changes in the micro-environment. Recent evid ce
shows that IL-4 binds strongly to the GAG side chains of
he a in,20 a property it shares with IL-8 and TNF-α. Since
heparin is a unique product of human mast cells, its secretion
onto the mast cell surface is likely to provide a pericellular envi-
ronm nt in which these cytokines are present in high concentra-
tion  to mediate local signalling effects pertinent to ongoing
inflammation.
Fig. 2 Proposed mediator functions of mast cell tryptase in asthma.
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Mast cell proteases
Tryptase, chymase, carboxypeptidase A and a cathepsin-G-like 
enzyme are also tightly bound to heparin which serves to pre-
serve integrity and direct the specificity of the enzymes. Tryptase 
is the major secretory component of mast cells and comprises in 
excess of 20% of the total granule content of protein, and ele-
vated concentrations have been detected in BAL fluid collected 
from patients with chronic severe asthma as well as from milder 
cases of atopic asthma. Evidence is emerging that this serine 
protease may act as a key mediator of disease. Tryptase is 
capable of participating in tissue remodelling, being able to 
cleave several components of the extracellular matrix (e. g., col-
lagen VI, fibronectin) in addition to activating matrix metallo-
proteases (stromelysin). The generation of kinins by tryptase may 
have important consequences, and this enzyme can also 
degrade certain neuropeptides postulated to have a regulatory 
role in asthma (VIP, CGRP). Interacting directly with the cell sur-
face, we have shown that tryptase can also enhance prolifera-
tion of epithelial cells, fibroblasts and smooth muscle cells, 
upregulate expression of ICAM-1, stimulate IL-8 release and 
induce eosinophil chemotaxis and activation, all of which are 
dependent upon preservation of the enzyme's catalytic site 
(Fig. 2).21-23
 Chymase, a protease co-released with tryptase by MCTC, can 
also cleave several structural proteins and activate other tissue-
degrading proteases (stromelysin, gelatinase A) as well as 
degrad  selective cytokines. In addition, chymase is one of the 
most potent secretagogues of mucus-secreting cells to have 
been described when injected into laboratory animals.24 We 
have shown that both tryptase and chymase, induce micro-
vascular leakage and granulocyte accumulation (Fig. 3). 
  Despite their potential importance as mediators, relatively 
l ttle is known of the expression of proteases in mast cells of the 
respiratory tract of asthmatic patients. Numbers of mast cells in 
bronchial tissue (as revealed by immunostaining for tryptase) 
are not greatly altered in asthma, although the elevated con-
c ntration of tryptase in BAL fluid indicates that the mast cells 
are in a more activated state. The process of protease synthesis 
d the kinetics of release from mast cells are not well under-
stood. Multiple cDNA have been cloned for tryptase, but the 
significance of this variation is not known. Sequences have also 
been derived for cDNA for chymase, and for other proteases 
which have been detected in mast cells including carboxypepti-
dase and cathepsin G. These advances now permit new 
approaches to be applied to answer basic questions on the biol-
ogy of mast-cell proteases and to better understand their roles 
in bronchial asthma.
Fig. 3 Proposed mediator functions of mast cell chymase in asthma.
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The triggering role of IgE
Cytokine-induced IgE may lead to disease progression by shift-
ing specificity from external to other antigens, including auto-
antigens, and through the formation of auto-antibodies against
IgE. Although the ability of IgE to bind to mast cells, and to
mediate antigen-induced degranulation is clear, its role in
maintaining chronic asthma is not fully understood. However,
patients with chronic disease have raised levels of allergen-
specific IgE in serum. IgE, particularly in its complex form, is
capable of mediating release of a range of cytokines via FcεR1
and FcεR2 (CD23). Since both high and Iow affinity IgE receptors
are upregulated on eosinophils and bronchial epithelial cells in
asthma patients, the opportunities for IgE to contribute to Iocal
inflammatory processes are numerous.
  The question is raised whether the IgE is specific for allergens,
or whether the spectrum of recognition widens during disease
progression to include viral antigens and auto-antigens, as for
chronic urticaria. Past analysis of IgE specificities has been lim-
ited to serological investigation f mixed IgE25 but the new tech-
nology will allow investigation of individual IgE molecules.It will
also be feasible to compare the molecular range of IgE found at
Iocal sites of inflammation with that in the blood. Methods for
amplifying the variable region genes used to encode IgE have
been developed and already reveal an unexpected asymmetric
usage of immunoglobulin VH genes in patients with asthma. In
the inflammatory environment, where there may be local
release of cytokines possibly exacerbated by viral infection, it is
conceivable that auto-antigens may be released. IgE antibodies
could therefore be generated against allergens, viral antigens
or auto-antigens. The high levels of IgE characteristic of chronic
asthma couid also induce auto-antibodies against IgE itself.26
These could have an important additional role in inflammation,
either by cross-linking IgE on the mast cell surface, or by gener-
ating immune complexes which stimulate mononuclear phago-
cytes to release cytokines.
Endothelial-leucocyte recruitment
Cytokine driven adivation ofthe microvasculature leadsto
increased expression of vascular adhesion molecules, medi-
ators and chemokines to promote leucocyte activation and
recruitment.
  The recruitment of leucocytes to sites of inflammation involves
awell co-ordinated and dynamic sequence of events in which
several cell adhesion molecules (CAM)and chemotactic
cytokines play an active role.271n vitro lines of evidence predict a
multi-step model involving:(i)initial low affinity selectin mole-
cule-dependent'>ascular rolling'(margination);(ii)Ieucocyte
activation by endothelial-derived chemo-a廿ractants(e.g., IL-8,
MCP-1);and(iii)atransition ofβ2-integrin-dependenthigh affin-
ity leucocyte adherence cytokine-mediated upregulation ofthe Ig
superfamily of adhesion proteins, ICAM and VCAM followed by
(iv)transendothelial migration invol>ing combinations of CAM.
  In asthma the presence of eosinophils and mononuclear cells
in the bronchial mucosa involves the initial recruitment from the
microvasculature. We have shown that within 6h of segmental
allergen challenge of sensitized asthmatic airways there occurs
marked endothelial upregulation of E-selectin and ICAM-1
accompanied by an influx of LFA-1+leucocytes comprising neu-
trophils and eosinophils.28 By 24 hthere was a marked increase
in activated T cells and eosinophils presentin BAL with variable
expression of VCAM-1,an adhesion molecule not normally
constitutively expressed. Because leucocyte recruitment occurs
so rapidly we suggest that the first step involves upregulation of
P-selectin (by histamine) and E-selectin (by TNF-α) released
from activated mast cells which mediate rolling through a lectin
interaction with the ligand sialyl Lewis x on the leucocyte sur-
face. The IgE-dependent secretion of newly formed TNF-α
would increase ICAM-1 expression while its interaction with
mast-cell-derived IL-4 stabilizes TNF-α-induced VCAM-1
expression.These CAM interactwiththe integrins LFA-1 and VLA-
4 to selectively recruit T cells and eosinophils.
  Preliminary immunohistochemistry studies on biopsies from
severe asthmatics from the National Dutch Asthma Hospital in
Davos have revealed a marked upregulation of ICAM-1 and
VCAM-1 in the absence of allergen exposure and while taking
high doses of corticosteroids.7 We suggest that in severe asthma
there is continued expression of endothelial CAM to promote
ongoing leucocyte recruitment and activation. Such a mecha-
nism would explainthe finding of elevated circulating and BAL
Ievels ofsolubIe CAM in symptomatic asthma.29
  The expression of E-selectin, ICAM-1 and VCAM-1 is con-
trolled by the nuclear transcription factor NF-kB, a heterodimer
p50/65 of which both subuhits contain the 300 amino acid NF-
kB/rel/dorsal (NRD) domain.27 The N-terminal end of NRD is
involved in specific binding to DNA, while the C-terminal end
Fig. 4 Schematic diagram to illustrate the mechanisms of NF-kB
transcription factor activation and function.
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contains the nuclear　 location signal　 (NLS), a cluster of positively
charged amino acids necessary for transiocation of NF-kB
across the nuclear membrane. NF-kB binds to the decameric
DNA sequence5'-GGAGNNccTTCC-3' found in the promoters of
a number of genes that are upregulated in inflammation, espe-
cially the CAM and specific cytokines (IL-2, IL-6, IL-8, members
of the IL-4 gene cluster and TNF-α; Fig. 4).
  Within the E-selectin promoter there are three closely spaced
binding sites for NF-kB clustered within a 40 bp segment and
two additional regulatory elements, NF-ELAM-1 and NF-ELAM-2.
The latter recognizes members of the cAMP-independent
ATF-CREB family of transcription factors and the former is
involved in the repression of the basal NF-kB enhancer in quies-
cent cells. Following cytokine exposure, all three NF-kB sites are
essential for maximal promoter activity. The promoter for the
human lCAM-1 gene contains binding sites for Sp-1,AP-1,AP-
2,AP-3, NF-kB and a putative silencer, whereas NF-kB alone
mediates VCAM-1 expression.
  A range of factors have been shown to initiate activation of
NF-kB, including TNF-α, IL-1, IL-2, LTB4 and viruses. Endothe-
lial cells express a cytoplasmic inhibitor of NF-kB activity, IkBα,
the over expression of which inhibits E-selectin and VCAM-1
transcription. IkBα binds selectively to NF-kB heterodimers and
prevents its nuclear uptake by binding to the NLS. A pathway
of NF-kB activation has been proposed that sequentially involves
phosphorylation of IxBα, followed by its specific chymotryptic
proteolysis which reveals the previously masked NLS site and
nuclear translocation. The activation is only transient since NF-
kB is also able to induce lkB mRNA transcription resul ing in re-
accumulation of IkBα and its functional inhibition of cytoplasmic
NF-kB. Reactive oxygen intermediates(ROI)serve as secondary
messengers of NF-kB activation and redox changes leading to
activation of chymo-trpytic IkBα protease through modification
of intracellular serpins. These intracellular events provide unique
opportunities to investigate NF-kB activation in severe asthma,
as it relates to increased CAM and cytokine expression, and to
investigate pharmacological intervention with potential thera-
peutic significance.26
The epithelium as a source of
pro-inflammatory products
There is persistent epithelial activation with production and
secretion of mediators and cytokines resulting in enhanced cell
recruitment, bronchoconstriction and airway wall remodelling.
  The bronchial epithelium has been viewed traditionally as a
passive barrier which serves as a target for the inflammatory
response, but it is also an important source of inflammatory
products including arachidonic acid products, endothelin, nitric
oxide (NO) and cytokines. In asthma, the increased expression
of ICAM-1, HLA-DR and CD44 demonstrates the capacity of the
epithelium to participate directly in inflammatory cell recruit-
ment and activation.
Arachidonic acid metabolism
We and others have shown that the epithelium is a major source
of 15-HETE and, although expression of immunoreactive 15-
lypoxygenase is unaltered,30 Shannon et al. have shown
increased enzyme activity in severe disease.31 Although 15-
HETE and 15-dihydroxy acids exhibit some mediator functions,
more active oxidate products of arachidonic acid are PGE2 and
PGF2α ith their opposite actions in bro chial smooth muscle.
We have recently shown that in mild-moderate asthma epithe-
lial expression of the inducible form of cyclo-oxygenase (COX2)
is enhanced over the constitutive form (COX1); achange that is
suppressed by corticosteroid treatment in pa allel with their clin-
ical efficacy.32 In asthma poorly controlled with corticosteroids,
COX2 upregulation might be expected to persist.
Endothelin
Human endothelin comprises three structurally distinct 21
amino acid peptides ET-1, ET-2 and ET-3 encoded on separate
genes. In additionto its potent vasoconstrictor property, ET-1 is
a potent contractor of airway smooth muscle mediated through
the ETB receptor subtype, whereas ET-2 and ET-3 have lower
binding affinities for ETB receptors.ET-1 is a mitogen for airway
smooth muscle and in fibroblasts is chemo-attractant, mitogenic
and provides an activating signal for collagen synthesis largely
mediatedthrough ETB receptors. ET-1 induces collagenase pro-
duction and is important in myofibroblast-mediated contraction
of granulation tissue.
Human bronchial epithelial cells cultured from the airways of
asthmatics secrete increased amounts of ET-1 which is sensitive
to inhibition with corticosteroids.33 ET-1 immunoreactivity in vivo
is also increased in the epithelium.34 In BAL,levels of ET-1 are
increased in proportion to the resting level of airflow obstruc-
tion.35 The importance of ET-1 as a novel bronchoconstrictor is
revealed by its capacity to reduce FEV1 by≧20% of baseline at
inhaled concentrations of 10-10-10-12mol/L. With effective cor-
ticosteroid treatment of asthma, both lavage ET-1 levels and ET-
1 expression in the epithelium return to those found in normal
subjects.
Nitric oxide
NO is a short lived, highly s luble, free radical which plays a
major role in cell-cell communication. It is generated enzymati-
ally from L-arginine by NO synthase which exists in both con-
stitutive and inducible soforms (iNOS). Both enzymes require
NADPH s co- ador and are inhibited by L-arginine analogues
such as NG-nitro-L-arginine (L-NNA) and NG-monomethyl-L-
arginine (L-NMMA) while the inducible form is selectively inhib-
ited by aminoguanidin . We have recentiy shown that iNOS
im u olocalizes strongly t  the bronchial epithelium in
bronchial biopsies from asthmatics but only rarely in those from
normal controts.36 Consistent with enhanced NO generation in
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airway mucosal inflammation is　the increased NO deteded in
exhaled air　of active asthma and rhinitis patients. In vitro iNOS
is induced in response　to IFN-γ, IL-1β　 and TNF-α and is inhib-
ited by corticosteroids. We have evidence that in corticosteroid-
responsive asthma iNOS in the epithelium is downregulated
and associated with a reduction in exhaled NO. Whilst NO
generated by iNOS also contributes to vasodilatation, when
upregulated, this enzyme has a greater synthetic capacity than
the constitutive enzymes in producing nanomolar concentra-
tions of NO. These are cytotoxic through the formation of per-
oxynitrate and hydroxyl radicals and  nitrosylation of key
mitochondrial enzymes. In severe asthma, the epithelium is
likely to be a major source of toxic levels of NO and as such
may provide a novel surrogate marker of disease activity and
response to treatment.
Cytokines
Human bronchial epithelial cells in vitro constitutively synthesize
and release IL-1β, IL-6, IL-8 and GM-CSF with greatly
enhanced production occurring on exposure to IL-1β or TNF-α..
Enhanced release of these cytokines has also been reported in
asthmatic epithelial cells in vitro. Application of IHC shows that
the bronchial epithelium in asthma is a particularly rich source
of IL-1β, IL-8 and GM-CSF.
  IL-8, a member of the α(C-x-C) chernokine family, is particu-
larly important in the expression of chronic and severe disease,
although it is usually regarded as a neutrophil chemo-
attractant. We have shown that IL-8 can induce human
eosinophils from asthmatis subjects to secrete IL-3, IL-5 and GM-
CSF. In an explant model of nasal polyp tissue, repeated allergen
exposure produces a supernatant exhibiting a markedly
enhanced eosinophil survival property. The explant supernatant
contains IL-2, IL-3 and IL-5 and particularly high amounts of GM-
CSF and IL-8.37 Using a range of blocking mAb, the eosinophil
survival properties imparted by the explant medium was shown to
be IL-8 and GM-CSF. These findings help explain why in atopic
but not in non-atopic subjects we were able to show that instilla-
tion of human recombinant IL-8 into the nasal cavity produced a
marked eosinophil in addition to neutral influx.
  IL-8 in bronchial biopsies from asthmatics and in the peripheral
circulation binds strongly to IgA.38 Thus, despite clear immunos-
taining for IL-8 in the epithelium, no free IL-8 can be detected in
detergent-extracted homogenates; however, IL-8-IgA complexes
can be readily detected with significantiy more being presented in
the allergic asthmatics. In patients WIth chronic severe asthma,
both free and complexed forms of IL-8 are present in mucosal tis-
sue and in serum. Thus, although{L-8 can be formed by many
cells in asthma, our studies pointtothe bronchial epithelium
beingthe major site of production and concenfiration ofthis
chemokine. It is of particular importance that IL-8 co-localizes
with a secretory IgA inthe epithelium, as secretory but not serum
IgA is able to markedly upregulate the eosinophil chemotactic
responseto IL-8 reaching an optimum of 10-10mol/L Under the
ame conditio s,the neutrophil response was inhibited. IL-8 is
also known to complex with the glycosaminoglycan side chains of
proteoglycans, an interaction that we have taken advantage of
when pu fying the cytokine from asthmatic BAL. The eosinophil-
specific properties of IL-8 are greatly enhanced when it is com-
plexed to a cell-bound matrix. These include the secretory piece of
IgA containing up to 20% N-linked oligosaccharide and proteo-
glycans, suc  as the granule products of mast cells and
e sinophils, nd CD44 which is expressed in greater amounts in
the asthmatis epithelium. We hypothesize that IL-8 binding regu-
lates the activity of and changes the target cell specificity of this
cytokine rendering it a potent attractant and activator of
eosinophils. In contrast to ET-1 and iNOS, corticosteroids only
partially inhibit IL-8 transcription by epithelial cells in vitro and
have no effect on free or complexed IL-8 levels in BAL fluid.That
this chemokine is regulated by NF-kB and is markedly increased
in proportion to asthma severity, increases its importance among
the chemokines as a prominent contributor to disease chronicity.
Epithelial repair
Epithelial damage results in persistent activation of repair mech-
anisms, abnormal epithelial-mesenchymal interactions and
detrimental remodelling ofthe airway.
Epithelial cell biology
Epit elial damage is a key feature of asthma with the extent of
damag  being relatedto disease activity. A recent study has
shown that impaired detection of bronchial obstruction, a char-
acte istic feature of severe disease, closely relates to the level of
eosinophi  infiltration and the extent of epithelial damage when
assessed i  bronchial biopsies. We have provided evidence
that the maj r structural site of damage is between the colum-
narand basal cells and between adjacent columnar cells, impli-
cat ng disruption to the desmosomes. The cause of increased
epithelial dysfunction in asthma is not understood although the
arginine-r ch basic proteins of the eosinophil and adive radicals
re onsidered to be important. The level of damage may reflect
either increased fragility or increased insult to the epithelium.To
understand theimportance of epithelial disruption in severe and
chronic asthma, It is important to understand the processes of
damage, repair a d regenerat on of the epithelium, and which
normal functions ofthe epithelium are compromised.
  On the basis of our pr liminary work and studies by others,
we propose the following steps in epithelial damage and repair:
  (1) Immediate damage and effects; selective cell loss due to
injury with loss of barrier fundtion.
  (2) Immediate res ons ; epithelial cells adjacent to areas of
damage reduce cell-substrate adhesion, increase cell migration
and form a fiemporary squamous barrier.
  (3) Proliferative respon e; division, differentiation and re-
mod ling leads to reformat on of fully functional differentiated
epithelium.
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(4) Ongoing damage; asthma occurring during the above
processes may further compromise epithelial integrity. Lack of
appropriate downregulation of the normal response may pro-
duce a similar effect.
Eosinophil-epithelial interactions
Cytokines
Eosinophils are a newly recognized source of cytokines includ-
ing IL-3, IL-4, IL-5, GM-CSF, IL-6,IL-8, TNF-α, MIP-1α, TGF-α
and TGF-β.12 Important among these for eosinophil survival are
IL-3, IL-5 and GM-CSF indicating an autocrine function.
Eosinophils exposed to these cytokines have their life expectancy
extended from days to weeks and are also more responsive to
chemo-attractant and mediator-secreting s imuli. Additionally,
since the three eosinophilopoietins antagonize the accelerating
effect of corticosteroids on eosinophil apoptosis, their sustained
production would serve to render the cells functionally'corticos-
teroid-resistant'.
  The use of blocking antibodies in our organ culture model
has clearly shown that IL-8 is important as an effector of
eosinophil survival by stimulating the release of IL-3, IL-5 and
GM-CSF.37 Within the limitations of available ELISA techniques,
these cytokines were not released but remained cell associated.
Eosinophils also synthesize and release IL-8 in response to PAF
and other stimuli, indicating that within the inflammatory focus
eosinophil survival and activation are supported by a cytokine
network dependent upon paracrine and autocrine loops. We
now wish to extend these observations in relation to asthma
chronicity by investigating the expression, intracellular localiza-
tion and mechanisms of release of IL-8, IL-5 and GM-CSF. Our
hypothesis is that the expression of eosinophil survival cytokines
is increased in bronchial tissue in proportion to disease severity
and that the intracellular cytokines are presented as a complex
with proteoglycans of the eosinophil granules similar to the role
of mast cell heparin in presenting IL-4. We propose that
cytokine release is dependent upon activation of cell-surface
immunoglobulin receptors.
  Secretory IgA has been suggested to  be the principal
immunoglobulin mediating eosinophil functions at mucosal sur-
faces.38 Eosinophil basic proteins are released in response to
slgA via a mechanism which is enhanced by IL-3, IL-5 and GM-
CSF. Functional effects of slgA are most probably mediated by
binding to either FcαR, whose expression on eosinophils is
increased in asthma, or to specific receptors for the secretory
component. We have shown that in asthma peripheral blood
eosinophils carry both IgA and the secretory component bound
to the cell surface. Unexpectedly, the concentrations of the secre-
tory component on asthmatic blood eosinophils was greater than
in a cultured epithelial cell line known to generate the secretory
component. We interpret this as the recirculation of eosinophils
from the mucosal site, a phenomenon previously suggested but
never proven. We have also noted strong synergism between
slgA and IL-8 induced eosinophil migration in vitro.38
  Although it is likely that enzymes of the 5-LO pathway are
upr gulated in eosinophils in asthma, this has not yet been
investigated. If accompanied by a decrease in PGE2 production
then unimportant autocrine cAMP-mediated inhibitory effect of
this mediator on a number of eosinophil responses is removed,
including the slgA induced release of basic granule proteins and
presumably cytokines. We have observed that eosinophils in
culture secrete PGE2 which is increased in the presence of PAF
or IL-5.Over 90% of the PGE2 is released into the fluid phase
and available for mediating negative feedback. In NSAID-
induced asthma, removal of PGE2 inhibition of mast cell and
eos nophil LTC4 production has been suggested.
 Eos nophils isol ted from the airways are spontaneously cyto-
toxic towards alveolar epithelial cells. However, in the airways of
sthmatics viable columnar cells that are shed from their basal
cell attachments will remain firmly fixed to the membrane via
hemidesmosome (α6β4) nd fibronectin-integrin adhesion.
Using a bovine bronchial epithelial explant, we suggest that
activated eosinophils mediate epithelial detachmentvia a cog-
nate interaction involving ICAM-1 and the subsequent release
of (i) etalloendopro e ses,(ii) oxidants, and (iii) arginine-rich
proteins.39
  Metalloendoproteases In BAL from patients with asthma we
hav  shown increased concentrations of the 92 Kd gelatinase
metal oproteinase atong with a range of other metalloendopro-
teases. Eos ophils are an important ource of the 92 Kd gelati-
n se which has a broad substrate specificity in being able to
degrade both basement membrane collagen type IV and inter-
stitial matrix mo ecules.40 Because ofthe extensive eosinophil
infilt ate in severe sthma, this enzyme is likely to be important
both in cell migration and tiss e remodelling, but other than
describing ts existence little is nown about its expression and
reg lati n.
  Oxidants Th  tissue damaging effect of the products of
eosinophil peroxidase (EPO) are indicated by the effectiveness
of antioxidants to inhibiteosinophil mediated injury to lung
epithelial cells and int rstitial m trix in vitro. EPO is released
asynchronously with ECP or MBPI and, as with many highly
charged proteins, it largely remains cell associated.Thus, in line
with our hypothesis that eosinophil-epithelial cell contact is
required for ffective epithelial disruption, we will investigate the
hypothesis that EPO along with reactive oxygen increases
epithelial fragility through pericellular proteoglycan and adhe-
si n glycoprotein degradation. A close-coupled mechanism
would senv   exclude naturally occurring antioxidants such as
GSH, vitamin E or albumen, and concentrate the delivery of the
oxidant injury.
  Basic proteins Considerable evidence exists forthe disrup-
tve effects of eosi ophil cationic proteins (MBP, ECP, EDN)
on epithelial integrit  in asthma. Their extreme cationicity
renders matrix proteoglycans as susceptible targets. A number
of proinflammatory cytokines, including IL-4, IL-8, IFN-γ and
b-FGF are tightly bound to GAG-side chains of highly O-
sulphated proteoglycans, an association which stabilizes the
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cytokine, localizes its activity and determines its specificity. Using
immunohistochemistry we suggest that IL-8 and IFN-Y localizes
to interepithelial clefts on account of their association with the
GAG of CD44 and N-sulphated carbohydrate moleties slgA.
Similarly, IL-4 binds to heparin on mast cells, to basic fibroblast
growth factor (bFGF), heparin SO4 in basement membranes
and TGF-β to decarin. Levels of IL-8, TGF-β and b-FGF are ele-
voted in BAL from asthmatics with further increases occurring 
with allergen challenge.41-43 We suggest the interaction of the 
eosinophil basic proteins with cytokine binding sites on matrix 
molecules results in the release of free cytokine so that a wider 
range of activity is achieved in severe disease. An additional 
possibility is that major basic protein and eosinophil cationic 
protein interact with the highly alkaline sensitive Ser-O-GAG 
linkage of proteoglycans to produce non-enzymatic hydrolysis 
to further affect tissue cytokine localization and activity.
Epithelial mast cell-epithelial interactions 
In mucosal biopsies mast cells aggregate both within the epithe-
lium and in relation to the connective tissue elements of the 
basement membrane and associated myofibroblasts. We have 
recently shown that, when assessed by flow cytometry on an 
H292 epithelial cell line, human mast cell tryptase is able to 
upregulate the cell surface expression of ICAM-1 to a similar
extent as TNF-α. A small increase in P-selectin and an apparent
downregulation of N-cadherin expression were also observed 
as the activity of tryptase was increased. Tryptase also stimu-
lated DNA synthesis in epithelial cells measured by 3H-thymi-
dine incorporation and produced a dose-related release of 
IL-8. Inhibition of tryptase with leupeptin or benzamidine HCI 
prevented these actions of tryptase indicating the obligatory 
requirement for an active catalytic site.17 These studies suggest 
an important role for mast cells in epithelial repair, in the 
recruitment of granulocytes and in rendering the lower respira-
tory tract vulnerable to human rhinovirus infection since the 
major type of human rhinovirus utilizes ICAM-1 to gain access 
to epithelial cells and upregulate cytokine production.
Epithelial cell-myofibroblast interactions
We have shown that the apparent thickening of the subepithelial 
basement membrane in asthma is due to the deposition of col-
lagen types I, III and V and fibronectin44 produced by proliferat-
ing myofibroblasts. The presence of tenascin in the lamina 
reticulosa indicates that this is a site of high matrix turnover and 
cell migration towards which both epithelial cells and myofi-
broblasts contribute. In addition to their capacity to secrete 
matrix proteins, we have recently shown that cultures of human 
bronchial subepithelial myofibroblasts produce GM-CSF, IL-6, 
IL-8 and SCF constitutively, and that the supernatant from cul-
tures could greatly extend eosinophil survival.45 GM-CSF tran-
scription demonstrated by RNase protection assay, was greatly
Fig. 5 Proposed interrelationship between airway inflammation and 
repair in asthma highlighting the important role of cytokines.
upregulated in the presence of TNFα and was accompanied by
secretion of GM-CSF which accounted for the majority of the
eosinophil survival capacity of the supernatants. The enhance-
ment of GM-CSF production by TNFα was inhibited in a dose-
dependent manner by prednisolone, but maximum inhibition
was not achieved until a dose of 1mmol/L was reached, a con-
centration far beyond that achieved therapeutically. These find-
ings suggest that human myofibroblasts located beneath the
bronchial epithelium establish close contact with eosinophils
and mast cells and as such play a critical role in upregulating
mucosal inflammation, especially in chronic disease.
An integrated model of asthma 
The complexities of human asthma as an inflammatory disorder 
are only just being appreciated. We have passed through the 
eras of believing that the disease is one of smooth muscle or 
mast cells or eosinophils or T cells to a picture where all these 
and other cells are involved in a co-operative fashion. Figure 5 
attempts to demonstrate this by showing a close interrelation-
ship between those factors responsible for inflammatory events 
and those involved in repair. Implicit in this model is inter-
dependency between the classical cells of inflammation and the 
formed elements of the airway. Varying contributions from each 
of these processes provides a rational basis for the variable clin-
ical phenotype and responses to therapeutic interventions.
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